Goldman Sachs Says Value Stocks, Not Cyclicals, Would Rally Most on Vaccine

Sep.21 -- A report by Goldman Sachs Group Inc. strategists, led by David Kostin, says value shares are a better way to bet on a Covid-19 vaccine than cyclical stocks, even though the latter have gained favor for capturing the trade. Juliette Saly reports on "Bloomberg Daybreak: Europe."
View on YouTube